induces immune profile liposome-based vaccine adjuvant Th1-biased immune profile ME-F-1122 vaccine adjuvant VAC: https://vac.niaid.nih.gov/view?id=103 Pubmed:27997339 Chemical Nature: Natural compound - Liposome formulation with TLR4 agonist Mechanism of Action: none Immune profile induced: Mixed Th1/Th2 Route of immunization: SQ, Combination of sub-cheek, IN and ID, IN prime with sub-cheek boosts, Point of Contact: Gary Fujii, Molecular Express Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=23313243 https://www.ncbi.nlm.nih.gov/pubmed/?term=26312747 https://www.ncbi.nlm.nih.gov/pubmed/?term=27997339 https://www.ncbi.nlm.nih.gov/pubmed/?term=35680499 https://www.ncbi.nlm.nih.gov/pubmed/?term=19835825 https://www.ncbi.nlm.nih.gov/pubmed/?term=21545821 https://www.ncbi.nlm.nih.gov/pubmed/?term=16713037 Ongoing clinical trials: none Jie Zheng Pubmed:21545821 ME-F-1122 Molecular Express Pubmed:23313243 Pubmed:26312747 Gary Fujii 103 vaccine adjuvant https://violinet.org/vaxjo/vaxjo_detail.php?c_vaxjo_id=500 Pubmed:35680499 Pubmed:16713037 ME-F-1122 is a Liposome-based vaccine adjuvant with TLR4 agonist to induce a mixed Th1/Th2 response.. https://github.com/vaccineontology/VO/issues/785 Pubmed:19835825